Genmab A/S
GNMSF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | 0.15 | -0.24 | 0.03 |
| FCF Yield | 2.81% | 0.40% | 2.09% | 2.74% |
| EV / EBITDA | 34.50 | 26.50 | 40.68 | 36.82 |
| Quality | ||||
| ROIC | 6.07% | 4.87% | 2.62% | 5.32% |
| Gross Margin | 94.32% | 93.84% | 94.13% | 94.77% |
| Cash Conversion Ratio | 1.11 | 0.15 | 1.18 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.61% | 11.87% | 13.56% | 13.83% |
| Free Cash Flow Growth | 62.05% | -81.13% | -33.30% | 31.89% |
| Safety | ||||
| Net Debt / EBITDA | -3.22 | -2.57 | -5.66 | -3.75 |
| Interest Coverage | 153.00 | 40.00 | 37.60 | 40.00 |
| Efficiency | ||||
| Inventory Turnover | 4.14 | 4.37 | 3.59 | 5.44 |
| Cash Conversion Cycle | 113.84 | -779.94 | -935.58 | -819.86 |